- Home
- GLOB vs CELC Comparison
GLOB vs CELC Comparison
Compare GLOB & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLOB | CELC |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GLOB | CELC |
|---|---|---|
| Price | $66.31 | $107.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $93.07 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 1.0M | 734.6K |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $2,484,891,000.00 | N/A |
| Revenue This Year | $3.37 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | $28.65 | ★ N/A |
| Revenue Growth | ★ 5.56 | N/A |
| 52 Week Low | $54.36 | $7.58 |
| 52 Week High | $228.98 | $116.44 |
Technical Indicators
Market Signals| Indicator | GLOB | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 55.86 |
| Support Level | $62.00 | $103.00 |
| Resistance Level | $69.81 | $116.44 |
| Average True Range (ATR) | 3.31 | 5.66 |
| MACD | -0.40 | -0.26 |
| Stochastic Oscillator | 47.08 | 49.36 |
Price Performance
Historical ComparisonAbout GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.